Patient data by UPN
| UPN . | Age, y/sex* . | Sample type . | FAB . | Blasts in sample, % . | Cytogenetics . | Mutations† . | MRD at end induction, %‡ . | Relapse . | Clinical outcome§ . |
|---|---|---|---|---|---|---|---|---|---|
| AML1 | 10.4/F | Pheresis | M0/M1 | 90 | t(16;21) | Unknown | 1.3 | Yes | DD |
| AML2 | 12.9/M | Pheresis | M5 | 90 | t(6;11) | Negative | 0 | Yes | DD |
| AML3 | 1.3/M | Pheresis | M5 | 88 | Ins(10;11) | Negative | 0 | Yes | DD |
| AML4 | 1.5/M | Pheresis | M4 | 40 | Normal | FLT3; AR, 0.04 | 22 | Yes | DD |
| AML5 | 12.3/F | Pheresis | M4 | 65 | Normal | Negative | 0 | No | Death from toxicity |
| AML6 | 6.9/F | BM | M2 | 40 | t(8;21) | Negative | 0 | Yes | Alive in second CR‖ |
| AML7 | 9.7/F | BM | M5 | 95 | t(10;11)(p11.2;q23) | Negative | 0.1 | Yes | DD |
| AML8 | 16.7/F | BM | M1 | 70 | +10 | Negative | 0 | Yes, CNS EOI1 | DD |
| AML9 | 16.8/M | BM | M2 | 70 | Normal | NPM1+ | 0 | No | Alive |
| AML10 | 18.1/M | BM | NR | 90 | +8 | FLT3; AR, 0.79 | 4.20 | Refractory EOI2 | Alive |
| AML11 | 15.7/M | BM | M1 | 82 | t(10;16) | Negative | 0 | Yes | Alive |
| AML12 | 18.9/M | BM | NR | 69 | Complex | Negative | Unknown, CR‖ | Yes | DD |
| NBM1 | 13.9/F | BM | |||||||
| NBM2 | 15.9/M | BM | |||||||
| NBM3 | 12.8/F | BM | |||||||
| NBM4 | 10.1/F | BM | |||||||
| NBM5 | 3.9/M | BM | |||||||
| NBM6 | 3.64/F | BM | |||||||
| NBM7 | 2.32/M | BM | |||||||
| NBM8 | 11.1/F | BM |
| UPN . | Age, y/sex* . | Sample type . | FAB . | Blasts in sample, % . | Cytogenetics . | Mutations† . | MRD at end induction, %‡ . | Relapse . | Clinical outcome§ . |
|---|---|---|---|---|---|---|---|---|---|
| AML1 | 10.4/F | Pheresis | M0/M1 | 90 | t(16;21) | Unknown | 1.3 | Yes | DD |
| AML2 | 12.9/M | Pheresis | M5 | 90 | t(6;11) | Negative | 0 | Yes | DD |
| AML3 | 1.3/M | Pheresis | M5 | 88 | Ins(10;11) | Negative | 0 | Yes | DD |
| AML4 | 1.5/M | Pheresis | M4 | 40 | Normal | FLT3; AR, 0.04 | 22 | Yes | DD |
| AML5 | 12.3/F | Pheresis | M4 | 65 | Normal | Negative | 0 | No | Death from toxicity |
| AML6 | 6.9/F | BM | M2 | 40 | t(8;21) | Negative | 0 | Yes | Alive in second CR‖ |
| AML7 | 9.7/F | BM | M5 | 95 | t(10;11)(p11.2;q23) | Negative | 0.1 | Yes | DD |
| AML8 | 16.7/F | BM | M1 | 70 | +10 | Negative | 0 | Yes, CNS EOI1 | DD |
| AML9 | 16.8/M | BM | M2 | 70 | Normal | NPM1+ | 0 | No | Alive |
| AML10 | 18.1/M | BM | NR | 90 | +8 | FLT3; AR, 0.79 | 4.20 | Refractory EOI2 | Alive |
| AML11 | 15.7/M | BM | M1 | 82 | t(10;16) | Negative | 0 | Yes | Alive |
| AML12 | 18.9/M | BM | NR | 69 | Complex | Negative | Unknown, CR‖ | Yes | DD |
| NBM1 | 13.9/F | BM | |||||||
| NBM2 | 15.9/M | BM | |||||||
| NBM3 | 12.8/F | BM | |||||||
| NBM4 | 10.1/F | BM | |||||||
| NBM5 | 3.9/M | BM | |||||||
| NBM6 | 3.64/F | BM | |||||||
| NBM7 | 2.32/M | BM | |||||||
| NBM8 | 11.1/F | BM |
AR, allelic ratio; BM, bone marrow; CR, complete remission; DD, death from disease; EOI, end of induction; FAB, French-American-British; F, female; M, male; MRD, minimal residual disease; NR, not reported; UPN, unique patient number.
Age at time of initial diagnosis.
Mutations tested: FLT3-ITD, NPM1, and CEBPA.
MRD by flow cytometry.
Outcome column indicates status at last contact.
CR by morphology.